Discontinuing Antidiabetic Medications for A1c of 5.6%

Rationale for Discontinuation

The American College of Physicians recommends deintensifying pharmacologic therapy for an A1c of 5.6%, as no trials show that targeting A1c levels below 6.5% improves clinical outcomes 1, 2
Pharmacologic treatment to achieve A1c below 6.5% has been associated with substantial harms, including increased risk of hypoglycemia and increased mortality in some studies 1
The ACCORD trial, which targeted A1c levels below 6.5%, was discontinued early due to increased overall and cardiovascular-related death and severe hypoglycemic events 1, 2

Discontinuing antidiabetic medications reduces the risk of hypoglycemia, a significant concern with many antidiabetic medications, according to the American Diabetes Association 3, 4
Decreasing medication burden and associated costs improves patient outcomes, as recommended by the American College of Physicians 1
Improving quality of life by reducing pill burden and potential side effects is a benefit of medication discontinuation, as noted by the Journal of the American Geriatrics Society 5
Avoiding unnecessary medication exposure when glycemic control is already excellent is a key consideration, as stated by the American College of Physicians 2

The American Diabetes Association recommends verifying the A1c value and confirming that the A1c of 5.6% is accurate and not an isolated reading 2
Assessing patient characteristics, such as comorbidities and cognitive/functional status, is crucial in determining the appropriate A1c target, according to the American College of Physicians 3
Considering medication class, such as insulin or oral medications with high risk of hypoglycemia, is essential in discontinuation decisions, as recommended by the American Diabetes Association 4, 5

The American Geriatrics Society recommends discontinuing medications gradually rather than all at once, particularly if the patient is on multiple agents 5
The American Diabetes Association suggests starting by eliminating medications with the highest risk of hypoglycemia first (insulin, sulfonylureas) 4
Monitoring glucose levels more frequently during the discontinuation period is crucial, as stated by the American College of Physicians 3
Emphasizing the continued importance of lifestyle modifications, including diet, exercise, and weight management, is essential, according to the American Diabetes Association 7

The American College of Physicians recommends scheduling follow-up A1c testing in 3-6 months to ensure glycemic control is maintained after discontinuation 6
Educating the patient about symptoms of hyperglycemia that would warrant reassessment is vital, as noted by the American Diabetes Association 4
Being aware that diabetes is a progressive disease, and some patients may need to restart medications in the future, is a key consideration, as stated by the American College of Physicians 6

The American Diabetes Association notes that for patients who achieved good control primarily through lifestyle modifications, the likelihood of maintaining good control after medication discontinuation is higher 7
For elderly patients or those with limited life expectancy, medication discontinuation at A1c of 5.6% is particularly appropriate, as the focus should be on avoiding hypoglycemia rather than tight glycemic control, according to the American Geriatrics Society 3, 4